Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation.
Atrial fibrillation
HATCH score
Left atrial dilation
Progression
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
22
08
2020
accepted:
22
10
2020
pubmed:
9
11
2020
medline:
3
11
2021
entrez:
8
11
2020
Statut:
ppublish
Résumé
Atrial fibrillation (AF) may progress from a non-permanent to a permanent form, and improvement in prediction may help in decision-making. In- and outpatients with non-permanent AF were enrolled in a prospective study and followed every 6 months. At baseline, 314 out of 523 patients (60%) had non-permanent AF (25.5% paroxysmal AF, 52.5% persistent, 2% first diagnosed AF). They were mostly males (188, 59.9%), median age 71 years [interquartile range (IQ) 62-77], median CHA
Identifiants
pubmed: 33161524
doi: 10.1007/s11739-020-02551-5
pii: 10.1007/s11739-020-02551-5
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1131-1140Informations de copyright
© 2020. Società Italiana di Medicina Interna (SIMI).
Références
Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC et al (2012) A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest 141(2):339–347
pubmed: 21622553
doi: 10.1378/chest.11-0340
pmcid: 21622553
Deng H, Bai Y, Shantsila A, Fauchier L, Potpara TS, Lip GYH (2017) Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. Clin Res Cardiol 106(10):813–823
pubmed: 28560516
pmcid: 5613037
doi: 10.1007/s00392-017-1123-0
Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M et al (2005) Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 149(3):489–496
pubmed: 15864238
doi: 10.1016/j.ahj.2004.09.053
pmcid: 15864238
de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al (2010) Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 55(8):725–731
pubmed: 20170808
doi: 10.1016/j.jacc.2009.11.040
pmcid: 20170808
De Vos CB, Breithardt G, Camm AJ, Dorian P, Kowey PR, Le Heuzey JY et al (2012) Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 163(5):887–893
pubmed: 22607868
doi: 10.1016/j.ahj.2012.02.015
pmcid: 22607868
Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M et al (2008) Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 29(9):1181–1189
pubmed: 18397874
doi: 10.1093/eurheartj/ehn139
pmcid: 18397874
Ogawa H, An Y, Ikeda S, Aono Y, Doi K, Ishii M et al (2018) Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. Stroke 49(10):2301–2308
pubmed: 30355097
doi: 10.1161/STROKEAHA.118.021396
pmcid: 30355097
Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M et al (2015) Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 36(5):281–287
pubmed: 25187524
doi: 10.1093/eurheartj/ehu307
pmcid: 25187524
Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC et al (2008) Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 29(18):2227–2233
pubmed: 18611964
pmcid: 2733739
doi: 10.1093/eurheartj/ehn324
Blum S, Meyre P, Aeschbacher S, Berger S, Auberson C, Briel M et al (2019) Incidence and predictors of atrial fibrillation progression: a systematic review and meta-analysis. Heart Rhythm 16(4):502–510
pubmed: 30366160
doi: 10.1016/j.hrthm.2018.10.022
Caldeira D, David C, Sampaio C (2012) Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 105(4):226–238
pubmed: 22633297
doi: 10.1016/j.acvd.2011.11.005
Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S (2013) Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 36(1):122–133
pubmed: 22978656
doi: 10.1111/j.1540-8159.2012.03513.x
Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, Essebag V, Eisenberg MJ, Wynant W et al (2012) Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 172(13):997–1004
pubmed: 22664954
doi: 10.1001/archinternmed.2012.2266
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962
pubmed: 27567408
doi: 10.1093/eurheartj/ehw210
pmcid: 27567408
Le CH (2016) The prevalence of anemia and moderate-severe anemia in the US population (NHANES 2003–2012). PLoS One 11(11):e0166635
pubmed: 27846276
pmcid: 5112924
doi: 10.1371/journal.pone.0166635
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
pubmed: 19414839
pmcid: 2763564
doi: 10.7326/0003-4819-150-9-200905050-00006
Group KAW (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2(Suppl1):1–138
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure 18(8):891–975
doi: 10.1002/ejhf.592
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270
pubmed: 25712077
doi: 10.1093/ehjci/jev014
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E et al (2011) Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 13(5):723–746
pubmed: 21515596
doi: 10.1093/europace/eur126
Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S et al (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31(19):2369–2429
pubmed: 20802247
doi: 10.1093/eurheartj/ehq278
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845
pubmed: 3203132
doi: 10.2307/2531595
Hoit BD (2014) Left atrial size and function: role in prognosis. J Am Coll Cardiol 63(6):493–505
pubmed: 24291276
doi: 10.1016/j.jacc.2013.10.055
D’Ascenzo F, Corleto A, Biondi-Zoccai G, Anselmino M, Ferraris F, di Biase L et al (2013) Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. Int J Cardiol 167(5):1984–1989
pubmed: 22626840
doi: 10.1016/j.ijcard.2012.05.008
Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM (2003) Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 41(6):1036–1043
pubmed: 12651054
doi: 10.1016/S0735-1097(02)02981-9
Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y et al (2001) Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 76(5):467–475
pubmed: 11357793
doi: 10.4065/76.5.467
Marchese P, Bursi F, Delle Donne G, Malavasi V, Casali E, Barbieri A et al (2011) Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr 12(3):214–221
pubmed: 21149290
doi: 10.1093/ejechocard/jeq176
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79–108
pubmed: 16458610
doi: 10.1016/j.euje.2005.12.014
Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A (2006) The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems. Eur Heart J 27(8):893–894
pubmed: 16543253
doi: 10.1093/eurheartj/ehi651
Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M et al (2019) Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace 21(7):1013–1022
pubmed: 30904925
doi: 10.1093/europace/euz032
pmcid: 30904925
Boriani G, Proietti M, Laroche C, Diemberger I, Popescu MI, Riahi S et al (2018) Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. Int J Cardiol 271:68–74
pubmed: 30001945
doi: 10.1016/j.ijcard.2018.05.034
pmcid: 30001945
Gulizia MM, Cemin R, Colivicchi F, De Luca L, Di Lenarda A, Boriani G et al (2019) Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. Europace 21(2):230–238
pubmed: 30060174
doi: 10.1093/europace/euy166
pmcid: 30060174
Marietta M, Banchelli F, Pavesi P, Manotti C, Quintavalla R, Sinigaglia T et al (2019) Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: a prospective, propensity score adjusted cohort study. Eur J Intern Med 62:9–16
pubmed: 30635146
doi: 10.1016/j.ejim.2018.12.010
pmcid: 30635146
Verdecchia P, D’Onofrio A, Russo V, Fedele F, Adamo F, Benedetti G et al (2019) Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. J Cardiovasc Med (Hagerstown) 20(2):66–73
doi: 10.2459/JCM.0000000000000744
Volterrani M, Iellamo F, Alberto C, Pasquale A, Salvatore P, Massimo P et al (2018) NOAC in “real world” patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. Intern Emerg Med 13(7):1069–1075
pubmed: 29956065
doi: 10.1007/s11739-018-1896-9
pmcid: 29956065
Godino C, Melillo F, Rubino F, Arrigoni L, Cappelletti A, Mazzone P et al (2019) Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. Intern Emerg Med 14(8):1259–1270
pubmed: 31073827
doi: 10.1007/s11739-019-02100-9
pmcid: 31073827
Marzona I, Proietti M, Vannini T, Tettamanti M, Nobili A, Medaglia M et al (2020) Sex-related differences in prevalence, treatment and outcomes in patients with atrial fibrillation. Intern Emerg Med 15(2):231–240
pubmed: 31243639
doi: 10.1007/s11739-019-02134-z
pmcid: 31243639
De With RR, Marcos EG, Dudink EAMP, Spronk HM, Crijns HJGM, Rienstra M et al (2020) Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. Europace 22(3):352–360
pubmed: 31865391
doi: 10.1093/europace/euz339
pmcid: 31865391
Barrett TW, Self WH, Wasserman BS, McNaughton CD, Darbar D (2013) Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. Am J Emerg Med 31(5): 792–7.
pubmed: 23478104
pmcid: 3655117
doi: 10.1016/j.ajem.2013.01.020
Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A, Boveda S et al (2020) European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace 22(8):1147–1148
pubmed: 32538434
pmcid: 7400488
doi: 10.1093/europace/euaa065
Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA et al (2016) EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 18(10):1455–1490
pubmed: 27402624
pmcid: 6392440
doi: 10.1093/europace/euw161
Strano S, Toni D, Ammirati F, Sanna T, Tomaino M, Brignole M et al (2019) Neuro-arrhythmology: a challenging field of action and research: a review from the Task Force of Neuro-arrhythmology of Italian Association of Arrhythmias and Cardiac Pacing. J Cardiovasc Med (Hagerstown) 20(11):731–744
doi: 10.2459/JCM.0000000000000866
Guichard JB, Nattel S (2017) Atrial cardiomyopathy: a useful notion in cardiac disease management or a passing fad? J Am Coll Cardiol 70(6):756–765
pubmed: 28774383
doi: 10.1016/j.jacc.2017.06.033
pmcid: 28774383
Keenan NG, Cueff C, Cimadevilla C, Brochet E, Lepage L, Detaint D et al (2010) Usefulness of left atrial volume versus diameter to assess thromboembolic risk in mitral stenosis. Am J Cardiol 106(8):1152–1156
pubmed: 20920656
doi: 10.1016/j.amjcard.2010.06.024
pmcid: 20920656
Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al (2016) “Real-world” management and outcomes of patients with paroxysmal vs non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace. 18(5):648–657
pubmed: 26826133
doi: 10.1093/europace/euv390
pmcid: 26826133
Inciardi RM, Rossi A (2019) Left atrium: a forgotten biomarker and a potential target in cardiovascular medicine. J Cardiovasc Med 20(12):797–808
doi: 10.2459/JCM.0000000000000886
Vincenti A, Genovesi S, Sonaglioni A, Binda G, Rigamonti E, Lombardo M et al (2019) Mechanical atrial recovery after cardioversion in persistent atrial fibrillation evaluated by bidimensional speckle tracking echocardiography. J Cardiovasc Med 20(11):745–751
doi: 10.2459/JCM.0000000000000864
Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M et al (2016) EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging 17(4):355–383
pubmed: 26864186
doi: 10.1093/ehjci/jev354
pmcid: 26864186
Giubertoni A, Boggio E, Ubertini E, Zanaboni J, Calcaterra E, Degiovanni A et al (2019) Atrial conduit function quantitation precardioversion predicts early arrhythmia recurrence in persistent atrial fibrillation patients. J Cardiovasc Med 20(4):169–179
doi: 10.2459/JCM.0000000000000756
Abhayaratna WP, Fatema K, Barnes ME, Seward JB, Gersh BJ, Bailey KR et al (2008) Left atrial reservoir function as a potent marker for first atrial fibrillation or flutter in persons > or = 65 years of age. Am J Cardiol 101(11):1626–1629
pubmed: 18489941
doi: 10.1016/j.amjcard.2008.01.051
Hirose T, Kawasaki M, Tanaka R, Ono K, Watanabe T, Iwama M et al (2012) Left atrial function assessed by speckle tracking echocardiography as a predictor of new-onset non-valvular atrial fibrillation: results from a prospective study in 580 adults. Eur Heart J Cardiovasc Imaging 13(3):243–250
pubmed: 22120846
doi: 10.1093/ejechocard/jer251